Related Experiment Video

Updated: Sep 27, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K

Gender Differences and Their Effects on Survival Outcomes in Lung Cancer Patients Treated With PD-1/PD-L1 Checkpoint

S Madala1, R Rasul2, K Singla3

  • 1Department of Internal Medicine, Staten Island University Hospital, Northwell Health, Staten Island, NY, USA.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|April 11, 2022
PubMed
Abstract

Insights

This meta-analysis found that Programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors benefit both men and women equally. These findings confirm that PD-1/PD-L1 inhibitors offer the same survival advantage for non-small cell lung cancer patients, irrespective of gender.

Area of Science:

  • Oncology
  • Immunology
  • Clinical Trials

Background:

  • Programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors have revolutionized lung cancer treatment.
  • However, the differential efficacy of these inhibitors based on gender in non-small cell lung cancer (NSCLC) remains unclear.

Approach:

  • A comprehensive meta-analysis was conducted using data from randomized controlled trials comparing PD-1/PD-L1 inhibitors with chemotherapy in NSCLC patients.
  • Overall survival (OS) and progression-free survival (PFS) were assessed using random-effects meta-analysis and meta-regression to evaluate gender-specific differences.

Key Points:

  • The meta-analysis included 12 studies for OS and 11 for PFS, encompassing 9270 and 6193 patients, respectively.
  • PD-1/PD-L1 inhibitors demonstrated a significant survival benefit over chemotherapy for both OS (HR=0.72) and PFS (HR=0.62).
  • No statistically significant differences in OS or PFS were observed between male and female patients receiving PD-1/PD-L1 inhibitors.

Conclusions:

  • This study is the first systematic review and meta-analysis to specifically investigate the impact of gender on PD-1/PD-L1 inhibitor efficacy in NSCLC.
  • Despite known biological immune response differences between genders, PD-1/PD-L1 inhibitors provide equivalent survival benefits for all NSCLC patients.
  • These findings support the use of PD-1/PD-L1 inhibitors as a standard treatment for NSCLC, irrespective of patient gender.
Keywords:
Immunotherapylung cancermeta-analysisnon-small cell lung canceroverall survivalprogression-free survival

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
472
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
319